{
    "clinical_study": {
        "@rank": "112851", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with\n      recurrent supratentorial low-grade glioma."
        }, 
        "brief_title": "Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma", 
        "completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Glioma", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the antitumor activity of Gliadel wafers (carmustine) in the treatment of\n           recurrent supratentorial low grade glioma.\n\n        -  Assess the toxicity of this therapy in these patients.\n\n      OUTLINE: Patients are stratified by disease (fibrillary astrocytoma vs oligodendroglioma or\n      mixed glioma).\n\n      Patients receive up to 8 Gliadel wafers (containing carmustine) implanted in the resected\n      tumor cavity.\n\n      Patients are followed every 2 months.\n\n      PROJECTED ACCRUAL: This study will accrue a maximum of 68 patients within 18-24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed recurrent primary low grade glioma including:\n\n               -  Fibrillary astrocytoma\n\n               -  Oligodendroglioma\n\n               -  Mixed glioma\n\n          -  Evidence of measurable enhancing or non-enhancing CNS neoplasm on MRI\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Hematocrit greater than 29%\n\n          -  Absolute neutrophil count greater than 1500/mm^3\n\n          -  Platelet count greater than 125,000/mm^3\n\n        Hepatic:\n\n          -  SGOT less than 1.5 times upper limit of normal (ULN)\n\n          -  Bilirubin less than 1.5 times ULN\n\n        Renal:\n\n          -  Creatinine less than 1.5 mg/dL\n\n          -  BUN less than 25 mg/dL\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy unless disease progression\n\n        Endocrine therapy:\n\n          -  Concurrent corticosteroids allowed (must be on stable dose for 1 week prior to study)\n\n          -  No concurrent immunosuppressive agents\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy unless disease progression\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No other concurrent medication that may interfere with study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003467", 
            "org_study_id": "1706", 
            "secondary_id": [
                "DUMC-1706-02-9R5", 
                "DUMC-1706-01-9R4", 
                "DUMC-000693-00-4", 
                "DUMC-1509-97-10", 
                "DUMC-1568-98-10R1", 
                "DUMC-1706-00-9R3", 
                "DUMC-97131", 
                "NCI-G98-1470", 
                "CDR0000066503"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "carmustine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "polifeprosan 20 with carmustine implant", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "surgical procedure", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carmustine"
        }, 
        "keyword": [
            "recurrent adult brain tumor", 
            "adult brain stem glioma", 
            "adult mixed glioma", 
            "adult anaplastic astrocytoma", 
            "adult pilocytic astrocytoma", 
            "adult oligodendroglioma"
        ], 
        "lastchanged_date": "June 19, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DUMC-1706-02-9R5"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Henry S. Friedman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003467"
        }, 
        "responsible_party": {
            "name_title": "Henry Friedman, MD", 
            "organization": "Duke UMC"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2009"
    }, 
    "geocoordinates": {
        "Duke Comprehensive Cancer Center": "35.994 -78.899"
    }
}